ProCE Banner Activity

Pharmacotherapies for Schizophrenia

Clinical Thought

Antipsychotic agents are the backbone of schizophrenia treatment. In recent years, several antipsychotic agents utilizing novel drug combinations, mechanisms of action, and modes of delivery have been introduced into the treatment paradigm, and additional options are in late stages of development. All these new and emerging options create a greater chance for clinicians to individualize treatment, consequently improving patient medication adherence and outcomes

Released: July 07, 2022

Expiration: July 06, 2023

No longer available for credit.



Leslie Citrome

Leslie Citrome, MD, MPH

Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York


This activity is supported by educational grants from Alkermes, Inc. and Teva Pharmaceuticals.

Provided by

ProCE Banner


Alkermes, Inc.

Teva Pharmaceuticals

Target Audience

NPs and PAs who care for patients with schizophrenia


Leslie Citrome, MD, MPH: speaker/consultant: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent, Cerevel, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, INmune Bio, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, MedavanteProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Praxis, Relmada, Reviva, Sage, Sunovion, Supernus, Takeda, and Teva; ownership interest: Bristol-Myers Squibb, Johnson & Johnson, Lilly, Merck, Pfizer, Reviva (options only).



Additional Information

Program Medium

This program has been made available online.